- Home
- VLGEA vs ERAS Comparison
VLGEA vs ERAS Comparison
Compare VLGEA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VLGEA | ERAS |
|---|---|---|
| Founded | 1937 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.8M | 439.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | VLGEA | ERAS |
|---|---|---|
| Price | $35.08 | $3.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 41.2K | ★ 1.9M |
| Earning Date | 12-02-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | ★ 4.59 | N/A |
| EPS | ★ 3.75 | N/A |
| Revenue | ★ $2,345,586,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | ★ 3.88 | N/A |
| 52 Week Low | $29.64 | $1.01 |
| 52 Week High | $40.15 | $3.38 |
Technical Indicators
Market Signals| Indicator | VLGEA | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 65.86 |
| Support Level | $34.26 | $2.81 |
| Resistance Level | $36.05 | $3.38 |
| Average True Range (ATR) | 0.86 | 0.24 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 48.09 | 87.23 |
Price Performance
Historical ComparisonAbout VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.